JOHNSON & JOHNSON REPORTS 75% TUMOR RESPONSE RATE IN ADVANCED PROSTATE CANCER WITH JNJ-6143, A FIRST-IN-CLASS RIPTAC™ MOLECULE

Reuters · 2d ago

Please log in to view news